BM-01DOSIMETRIC HOTSPOTS ARE THE MOST POWERFUL DOSIMETRIC PREDICTOR OF LOCAL CONTROL IN NSCLC BRAIN METASTASES

BACKGROUND: There is scant data on actionable parameters that may improve local control (LC) after SRS for brain metastases. We evaluated the impact of various patient, tumor, and dosimetric variables on LC of NSCLC brain metastases with SRS. METHODS: Patients with NSCLC brain metastases treated wit...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2014-11, Vol.16 (Suppl 5), p.v32-v32
Main Authors: Abraham, Christopher, Garsa, Adam, Badiyan, Shahed, Dryzmala, Robert, Yang, Deshan, DeWees, Todd, Simpson, Joseph, Fouke, Sarah, Robinson, Cliff
Format: Article
Language:English
Subjects:
Abstracts
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page v32
container_issue Suppl 5
container_start_page v32
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 16
creator Abraham, Christopher
Garsa, Adam
Badiyan, Shahed
Dryzmala, Robert
Yang, Deshan
DeWees, Todd
Simpson, Joseph
Fouke, Sarah
Robinson, Cliff
description BACKGROUND: There is scant data on actionable parameters that may improve local control (LC) after SRS for brain metastases. We evaluated the impact of various patient, tumor, and dosimetric variables on LC of NSCLC brain metastases with SRS. METHODS: Patients with NSCLC brain metastases treated with single fraction SRS without prior metastasectomy or SRS to the same lesion were identified. Brain MRI imaging was reviewed from time of SRS until death or last follow up. LC was scored for each lesion as stability or decrease in the size of the treated metastasis. Dose volume histograms (DVH) were collected for each lesion and evaluated with a custom DVH tool. V18-V50Gy, D10, D50, D90, dose mean, maximum, minimum, and median were extracted as were dose gradient index and RTOG conformity index. Univariate and multivariate Cox Regression were used to identify factors predictive of LC, and LC was estimated using the Kaplan-Meier method. RESULTS: 612 brain metastases in 299 patients were identified, yielding 122 local failures. On univariate analysis, lack of prior whole brain, lack of whole brain < 2 months, Perfexion machine model, increasing dose, increasing isodose, fewer shots, increasing V18-V40, decreasing volume, and increasing conformity index were associated with increased LC (p < 0.05). On multivariate analysis (MVA), decreasing volume (HR 1.359, 95% CI 1.197-1.543), increasing V32Gy (HR 0.069 95% CI 0.018-0.264), and increasing isodose (HR 0.953, 95% CI 0.911-0.996. were associated with increased LC (p < 0.05). CONCLUSIONS: Significant plan quality variation exists for a given prescription dose for SRS, and prescription dose is not predictive of LC. Optimizing the volume of tumor receiving high dose (such as V32) for a given prescription dose represents an actionable variable to drive treatment planning during SRS for brain metastases. Analysis of a larger number of lesions within a multi-institutional registry (CONDR-IMD) will further clarify such parameters.
doi_str_mv 10.1093/neuonc/nou240.1
format article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4217909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_4217909</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_42179093</originalsourceid><addsrcrecordid>eNqlT11LwzAUDaLgnD7v9f6BuiRbu-1F6LKUFtKmJBEfQzerVrZ0tFbw3y8MH9yzcC_ncM8HXIQmBD8SvJpNXT20bjd17UDn_nSFRiSksyBcRtH1mdNgGZLFLbrr-0-MKQkjMkJunQeYbKTOcm5UxiCVRpd-IVYcTMohl9pAKV-4Sp4F_HGWim8yZqQCmYCQLBbAZGGUFJAVUGgmGKxV7LkPxNoP1_fo5q3a9_XDL47RU8INS4PjsD3Ur7vafXXV3h675lB1P7atGnupuObDvrffdk7JYuXf_nfBCSK0Xl0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>BM-01DOSIMETRIC HOTSPOTS ARE THE MOST POWERFUL DOSIMETRIC PREDICTOR OF LOCAL CONTROL IN NSCLC BRAIN METASTASES</title><source>NCBI_PubMed Central（免费）</source><source>Oxford Journals</source><creator>Abraham, Christopher ; Garsa, Adam ; Badiyan, Shahed ; Dryzmala, Robert ; Yang, Deshan ; DeWees, Todd ; Simpson, Joseph ; Fouke, Sarah ; Robinson, Cliff</creator><creatorcontrib>Abraham, Christopher ; Garsa, Adam ; Badiyan, Shahed ; Dryzmala, Robert ; Yang, Deshan ; DeWees, Todd ; Simpson, Joseph ; Fouke, Sarah ; Robinson, Cliff</creatorcontrib><description>BACKGROUND: There is scant data on actionable parameters that may improve local control (LC) after SRS for brain metastases. We evaluated the impact of various patient, tumor, and dosimetric variables on LC of NSCLC brain metastases with SRS. METHODS: Patients with NSCLC brain metastases treated with single fraction SRS without prior metastasectomy or SRS to the same lesion were identified. Brain MRI imaging was reviewed from time of SRS until death or last follow up. LC was scored for each lesion as stability or decrease in the size of the treated metastasis. Dose volume histograms (DVH) were collected for each lesion and evaluated with a custom DVH tool. V18-V50Gy, D10, D50, D90, dose mean, maximum, minimum, and median were extracted as were dose gradient index and RTOG conformity index. Univariate and multivariate Cox Regression were used to identify factors predictive of LC, and LC was estimated using the Kaplan-Meier method. RESULTS: 612 brain metastases in 299 patients were identified, yielding 122 local failures. On univariate analysis, lack of prior whole brain, lack of whole brain &lt; 2 months, Perfexion machine model, increasing dose, increasing isodose, fewer shots, increasing V18-V40, decreasing volume, and increasing conformity index were associated with increased LC (p &lt; 0.05). On multivariate analysis (MVA), decreasing volume (HR 1.359, 95% CI 1.197-1.543), increasing V32Gy (HR 0.069 95% CI 0.018-0.264), and increasing isodose (HR 0.953, 95% CI 0.911-0.996. were associated with increased LC (p &lt; 0.05). CONCLUSIONS: Significant plan quality variation exists for a given prescription dose for SRS, and prescription dose is not predictive of LC. Optimizing the volume of tumor receiving high dose (such as V32) for a given prescription dose represents an actionable variable to drive treatment planning during SRS for brain metastases. Analysis of a larger number of lesions within a multi-institutional registry (CONDR-IMD) will further clarify such parameters.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/nou240.1</identifier><language>eng</language><publisher>Oxford University Press</publisher><subject>Abstracts</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (Suppl 5), p.v32-v32</ispartof><rights>Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2014. 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217909/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217909/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids></links><search><creatorcontrib>Abraham, Christopher</creatorcontrib><creatorcontrib>Garsa, Adam</creatorcontrib><creatorcontrib>Badiyan, Shahed</creatorcontrib><creatorcontrib>Dryzmala, Robert</creatorcontrib><creatorcontrib>Yang, Deshan</creatorcontrib><creatorcontrib>DeWees, Todd</creatorcontrib><creatorcontrib>Simpson, Joseph</creatorcontrib><creatorcontrib>Fouke, Sarah</creatorcontrib><creatorcontrib>Robinson, Cliff</creatorcontrib><title>BM-01DOSIMETRIC HOTSPOTS ARE THE MOST POWERFUL DOSIMETRIC PREDICTOR OF LOCAL CONTROL IN NSCLC BRAIN METASTASES</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>BACKGROUND: There is scant data on actionable parameters that may improve local control (LC) after SRS for brain metastases. We evaluated the impact of various patient, tumor, and dosimetric variables on LC of NSCLC brain metastases with SRS. METHODS: Patients with NSCLC brain metastases treated with single fraction SRS without prior metastasectomy or SRS to the same lesion were identified. Brain MRI imaging was reviewed from time of SRS until death or last follow up. LC was scored for each lesion as stability or decrease in the size of the treated metastasis. Dose volume histograms (DVH) were collected for each lesion and evaluated with a custom DVH tool. V18-V50Gy, D10, D50, D90, dose mean, maximum, minimum, and median were extracted as were dose gradient index and RTOG conformity index. Univariate and multivariate Cox Regression were used to identify factors predictive of LC, and LC was estimated using the Kaplan-Meier method. RESULTS: 612 brain metastases in 299 patients were identified, yielding 122 local failures. On univariate analysis, lack of prior whole brain, lack of whole brain &lt; 2 months, Perfexion machine model, increasing dose, increasing isodose, fewer shots, increasing V18-V40, decreasing volume, and increasing conformity index were associated with increased LC (p &lt; 0.05). On multivariate analysis (MVA), decreasing volume (HR 1.359, 95% CI 1.197-1.543), increasing V32Gy (HR 0.069 95% CI 0.018-0.264), and increasing isodose (HR 0.953, 95% CI 0.911-0.996. were associated with increased LC (p &lt; 0.05). CONCLUSIONS: Significant plan quality variation exists for a given prescription dose for SRS, and prescription dose is not predictive of LC. Optimizing the volume of tumor receiving high dose (such as V32) for a given prescription dose represents an actionable variable to drive treatment planning during SRS for brain metastases. Analysis of a larger number of lesions within a multi-institutional registry (CONDR-IMD) will further clarify such parameters.</description><subject>Abstracts</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqlT11LwzAUDaLgnD7v9f6BuiRbu-1F6LKUFtKmJBEfQzerVrZ0tFbw3y8MH9yzcC_ncM8HXIQmBD8SvJpNXT20bjd17UDn_nSFRiSksyBcRtH1mdNgGZLFLbrr-0-MKQkjMkJunQeYbKTOcm5UxiCVRpd-IVYcTMohl9pAKV-4Sp4F_HGWim8yZqQCmYCQLBbAZGGUFJAVUGgmGKxV7LkPxNoP1_fo5q3a9_XDL47RU8INS4PjsD3Ur7vafXXV3h675lB1P7atGnupuObDvrffdk7JYuXf_nfBCSK0Xl0</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Abraham, Christopher</creator><creator>Garsa, Adam</creator><creator>Badiyan, Shahed</creator><creator>Dryzmala, Robert</creator><creator>Yang, Deshan</creator><creator>DeWees, Todd</creator><creator>Simpson, Joseph</creator><creator>Fouke, Sarah</creator><creator>Robinson, Cliff</creator><general>Oxford University Press</general><scope>5PM</scope></search><sort><creationdate>20141101</creationdate><title>BM-01DOSIMETRIC HOTSPOTS ARE THE MOST POWERFUL DOSIMETRIC PREDICTOR OF LOCAL CONTROL IN NSCLC BRAIN METASTASES</title><author>Abraham, Christopher ; Garsa, Adam ; Badiyan, Shahed ; Dryzmala, Robert ; Yang, Deshan ; DeWees, Todd ; Simpson, Joseph ; Fouke, Sarah ; Robinson, Cliff</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_42179093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Abstracts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abraham, Christopher</creatorcontrib><creatorcontrib>Garsa, Adam</creatorcontrib><creatorcontrib>Badiyan, Shahed</creatorcontrib><creatorcontrib>Dryzmala, Robert</creatorcontrib><creatorcontrib>Yang, Deshan</creatorcontrib><creatorcontrib>DeWees, Todd</creatorcontrib><creatorcontrib>Simpson, Joseph</creatorcontrib><creatorcontrib>Fouke, Sarah</creatorcontrib><creatorcontrib>Robinson, Cliff</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abraham, Christopher</au><au>Garsa, Adam</au><au>Badiyan, Shahed</au><au>Dryzmala, Robert</au><au>Yang, Deshan</au><au>DeWees, Todd</au><au>Simpson, Joseph</au><au>Fouke, Sarah</au><au>Robinson, Cliff</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BM-01DOSIMETRIC HOTSPOTS ARE THE MOST POWERFUL DOSIMETRIC PREDICTOR OF LOCAL CONTROL IN NSCLC BRAIN METASTASES</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2014-11-01</date><risdate>2014</risdate><volume>16</volume><issue>Suppl 5</issue><spage>v32</spage><epage>v32</epage><pages>v32-v32</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>BACKGROUND: There is scant data on actionable parameters that may improve local control (LC) after SRS for brain metastases. We evaluated the impact of various patient, tumor, and dosimetric variables on LC of NSCLC brain metastases with SRS. METHODS: Patients with NSCLC brain metastases treated with single fraction SRS without prior metastasectomy or SRS to the same lesion were identified. Brain MRI imaging was reviewed from time of SRS until death or last follow up. LC was scored for each lesion as stability or decrease in the size of the treated metastasis. Dose volume histograms (DVH) were collected for each lesion and evaluated with a custom DVH tool. V18-V50Gy, D10, D50, D90, dose mean, maximum, minimum, and median were extracted as were dose gradient index and RTOG conformity index. Univariate and multivariate Cox Regression were used to identify factors predictive of LC, and LC was estimated using the Kaplan-Meier method. RESULTS: 612 brain metastases in 299 patients were identified, yielding 122 local failures. On univariate analysis, lack of prior whole brain, lack of whole brain &lt; 2 months, Perfexion machine model, increasing dose, increasing isodose, fewer shots, increasing V18-V40, decreasing volume, and increasing conformity index were associated with increased LC (p &lt; 0.05). On multivariate analysis (MVA), decreasing volume (HR 1.359, 95% CI 1.197-1.543), increasing V32Gy (HR 0.069 95% CI 0.018-0.264), and increasing isodose (HR 0.953, 95% CI 0.911-0.996. were associated with increased LC (p &lt; 0.05). CONCLUSIONS: Significant plan quality variation exists for a given prescription dose for SRS, and prescription dose is not predictive of LC. Optimizing the volume of tumor receiving high dose (such as V32) for a given prescription dose represents an actionable variable to drive treatment planning during SRS for brain metastases. Analysis of a larger number of lesions within a multi-institutional registry (CONDR-IMD) will further clarify such parameters.</abstract><pub>Oxford University Press</pub><doi>10.1093/neuonc/nou240.1</doi></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (Suppl 5), p.v32-v32
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4217909
source NCBI_PubMed Central（免费）; Oxford Journals
subjects Abstracts
title BM-01DOSIMETRIC HOTSPOTS ARE THE MOST POWERFUL DOSIMETRIC PREDICTOR OF LOCAL CONTROL IN NSCLC BRAIN METASTASES
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T01%3A37%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BM-01DOSIMETRIC%20HOTSPOTS%20ARE%20THE%20MOST%20POWERFUL%20DOSIMETRIC%20PREDICTOR%20OF%20LOCAL%20CONTROL%20IN%20NSCLC%20BRAIN%20METASTASES&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Abraham,%20Christopher&rft.date=2014-11-01&rft.volume=16&rft.issue=Suppl%205&rft.spage=v32&rft.epage=v32&rft.pages=v32-v32&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/nou240.1&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_4217909%3C/pubmedcentral%3E%3Cgrp_id%3Ecdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_42179093%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true